Orlowski, Robert Z.

Reprogrammed marrow adipocytes contribute to myeloma-induced bone disease

Liu, H., He, J., Koh, S. P., Zhong, Y., Liu, Z., Wang, Z., Zhang, Y., Li, Z., Tam, B. T., Lin, P., et al. (2019) · Science Translational Medicine

Multiple Myeloma Research and TreatmentsBone Metabolism and Diseases

Cited by 113

p38 MAPK in Myeloma Cells Regulates Osteoclast and Osteoblast Activity and Induces Bone Destruction

He, J., Liu, Z., Zheng, Y., Qian, J., Li, H., Lu, Y., Xu, J., Hong, B., Zhang, M., Lin, P., et al. (2012) · Cancer Research

Bone Metabolism and DiseasesMultiple Myeloma Research and Treatments

Cited by 91

Pembrolizumab combined with lenalidomide and low‐dose dexamethasone for relapsed or refractory multiple myeloma: phase I KEYNOTE‐023 study

Mateos, M., Orlowski, R. Z., Ocio, E. M., Rodríguez‐Otero, P., Reece, D., Moreau, P., Munshi, N., Avigan, D. E., Siegel, D. S., Ghori, R., et al. (2019) · British Journal of Haematology

Multiple Myeloma Research and TreatmentsMultiple Sclerosis Research Studies

Cited by 73

Antigen-mediated regulation in monoclonal gammopathies and myeloma

Nair, S., Sng, J., Boddupalli, C. S., Seckinger, A., Chesi, M., Fulciniti, M., Zhang, L., Rauniyar, N., Lopez, M., Neparidze, N., et al. (2018) · JCI Insight

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 60

Absence of mutations in cereblon (CRBN) and DNA damage-binding protein 1 (DDB1) genes and significance for IMiD therapy

Thakurta, A., Gandhi, A. K., Waldman, M. F., Bjorklund, C., Ning, Y., Mendy, D., Schafer, P., Lopez-Girona, A., Lentzsch, S., Schey, S. A., et al. (2014) · Leukemia

Protein Degradation and InhibitorsMultiple Myeloma Research and Treatments

Cited by 56

Single cell clonotypic and transcriptional evolution of multiple myeloma precursor disease

Dang, M., Han, G., Lee, H. C., Patel, K. K., Becnel, M. R., Wang, R., Thomas, S. K., Hao, D., Chu, Y., Weber, D. M., et al. (2023) · Cancer Cell

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 55

Phase 3 Randomized Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Patients with Newly Diagnosed Multiple Myeloma (NDMM) Ineligible for Transplant (MAIA)

Facon, T., Kumar, S. K., Plesner, T., Orlowski, R. Z., Moreau, P., Bahlis, N., Basu, S., Nahi, H., Hulin, C., Quach, H., et al. (2018) · Blood

Multiple Myeloma Research and TreatmentsMonoclonal and Polyclonal Antibodies Research

Cited by 50

Siltuximab (CNTO 328) with lenalidomide, bortezomib and dexamethasone in newly-diagnosed, previously untreated multiple myeloma: an open-label phase I trial

Shah, J. J., Feng, L., Thomas, S. K., Berkova, Z., Weber, D. M., Wang, M., Qazilbash, M. H., Champlin, R. E., Mendoza, T. R., Cleeland, C., et al. (2016) · Blood Cancer Journal

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 35

Longer Term Follow up of the  Randomized Phase III Trial SWOG S0777: Bortezomib, Lenalidomide and Dexamethasone Vs. Lenalidomide and Dexamethasone in Patients (Pts) with Previously Untreated Multiple Myeloma without an Intent for Immediate Autologous Stem Cell Transplant (ASCT)

Durie, B. G., Hoering, A., Sexton, R., Abidi, M. H., Epstein, J., Rajkumar, S. V., Dispenzieri, A., Kahanic, S. P., Thakuri, M. C., Reu, F. J., et al. (2018) · Blood

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 34

A meta-analysis of genome-wide association studies of multiple myeloma among men and women of African ancestry

Du, Z., Weinhold, N., Song, G. C., Rand, K. A., Van Den Berg, D. J., Hwang, A. E., Sheng, X., Hom, V., Ailawadhi, S., Nooka, A. K., et al. (2020) · Blood Advances

Multiple Myeloma Research and TreatmentsGenetic Associations and Epidemiology

Cited by 31

E3A06: Randomized phase III trial of lenalidomide versus observation alone in patients with asymptomatic high-risk smoldering multiple myeloma.

Lonial, S., Jacobus, S. J., Weiss, M., Kumar, S., Orlowski, R. Z., Kaufman, J. L., Yacoub, A., Buadi, F., O'Brien, T. E., Matous, J., et al. (2019) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsBone health and treatments

Cited by 28

The Novel Anticancer Agent JNJ-26854165 Induces Cell Death through Inhibition of Cholesterol Transport and Degradation of ABCA1

Jones, R. J., Gu, D., Bjorklund, C. C., Kuiatse, I., Remaley, A. T., Bashir, T., Vreys, V., & Orlowski, R. Z. (2013) · The Journal of Pharmacology and Experimental Therapeutics

Cholesterol and Lipid MetabolismCancer, Lipids, and Metabolism

Cited by 26

Plasma cell myeloma with RAS/BRAF mutations is frequently associated with a complex karyotype, advanced stage disease, and poorer prognosis

Li, N., Lin, P., Zuo, Z., You, M. J., Shuai, W., Orlowski, R., Manasanch, E. E., Li, S., Xu, J., Garces, S., et al. (2023) · Cancer Medicine

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 19

Genomics define malignant transformation in myeloma precursor conditions

Maura, F., Bergsagel, P. L., Ziccheddu, B., Kumar, S., Maclachlan, K., Derkach, A., Garces, J.-J., Firestone, R., Braggio, E., Asmann, Y., et al. (2026) · Journal of Clinical Oncology

Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research

Cited by 18

Outcome of patients with immunoglobulin light-chain amyloidosis with lung, liver, gastrointestinal, neurologic, and soft tissue involvement after autologous hematopoietic stem cell transplantation

Afrough, A., Saliba, R. M., Hamdi, A., El Fakih, R., Varma, A., Dinh, Y. T., Rondon, G., Cornelison, A. M., Shah, N. D., Bashir, Q., et al. (2015) · Biology of Blood and Marrow Transplantation

Amyloidosis: Diagnosis, Treatment, OutcomesMultiple Myeloma Research and Treatments

Cited by 6